ABSTRACT:
Diabetic kidney disease (DKD) is a major global public health concern due to its high prevalence and mortality, and high healthcare cost. Conventional Western therapies for DKD fail to provide favourable efficacy. Chinese medicine (CM) has been widely used to combat DKD in China and other Asian countries. The clinical effects and mechanism of CM in treating DKD have not been fully elucidated. This review summarizes current knowledge of CM therapeutic modalities for DKD, especially Chinese herbal medicine (CHM), and potential mechanisms.
Diabetic kidney disease (DKD) is one of the most severe microvascular complications of diabetes and the leading cause of end-stage renal disease (ESRD) in developed countries. In 2013, incidence of ESRD due to DKD in the United States and Japan was 45.9% 1 and 43.8%, 2 respectively.
Current evidence shows that early administration of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), improvement in glycaemic control and lipid-lowering therapy are the first-line treatment for managing DKD. 3 Unfortunately, these treatments have some disadvantages: ACEI/ARB are contraindicated for patients with severe renal impairment and have severe side effects 4 ; intensive blood glucose control can lead to hypoglycaemia 5 ; and studies evaluating the renoprotective effect of statin therapy on DKD have contradictory findings. 6 Chinese medicine (CM) is a source of medical knowledge gained from clinical experience. Literature records of CM treating proteinuria and oedema, which are the key clinical manifestations of DKD, can be traced back to the Han dynasty (206 BCE to 220 CE). This theory has been refined over long empirical practice, resulting in diverse and numerous forms of treatments. This article reviews modern treatments of DKD with CM based on literature reports.
TREATING DIABETIC KIDNEY DISEASE WITH CHINESE MEDICINE
General principles CM is a medical system that treats patients based on analysing their presenting signs and symptoms, namely syndrome differentiation. Applying the Delphi method, CM experts have classified the syndrome patterns of DKD into qi deficiency, blood stasis, yin deficiency, turbid dampness, phlegm dampness, yang deficiency, blood deficiency and qi stagnation. 7 Cross-sectional studies have indicated that the most common syndrome pattern of DKD is deficiency of both qi and yin with blood stasis. 8 Thus, based on the syndrome pattern differentiation, the basic treatment principles of DKD include tonifying qi, nourishing yin, reinforcing the kidney, strengthening the spleen, promoting circulation and removing stasis, clearing the collaterals and resolving dampness. Chinese herbal medicine (CHM) is the main form of CM treatment for DKD. CHM is comprised of medicinal plants, minerals or animal materials. CHMs can be administered in various forms, including decoction, patent medicine, injection, single-herb extract, acupoint herbal patch and enema. For DKD, decoction is the more common form of administration.
Clinical efficacy of CHM in diabetic kidney disease
In China, numerous CHMs are prescribed for DKD. 9 The efficacies of classic Chinese prescriptions, such as Bawei Dihuang pill (八味地黄丸), Guizhi Fuling pill (桂枝茯苓丸), Liuwei Dihuang pill (六味地黄丸) and Wenpi decoction (温 脾汤), have been validated by clinical trials. 10 A recently developed proprietary CHM decoction has been found to be efficacious through a placebo-controlled randomized trial in decreasing 24-h urinary protein and improving estimated glomerular filtration rate (eGFR). 11 Other CHMs have been investigated for their therapeutic efficacies, some have been found to reduce urinary albumin excretion rate (UAER), and when combined with ACEI/ARBs, UAER was decreased even further. 12 Active components extracted from single herbs are also used in DKD. For example, extract of aibika flower (Abelmoschus manihot (L.) Medik.; 黄蜀葵花) has been found to lower serum creatinine, reduce urinary protein and elevate serum albumin compared with ACE/ARB. 13 Extract of tripterygium root (Tripterygium wilfordii Hook. F.; 雷公藤) was shown to significantly decrease proteinuria and slow the decline of eGFR compared with valsartan. 14 Some CHM prescriptions used to treat DKD have added effects of regulating blood lipids and decreasing blood glucose. 15 Ongoing clinical trials will provide further evidence of the effectiveness of CHMs in treating DKD (Tangshen formula, ChiCTR-TRC-13003566; Shenyan Kangfu tablets, ChiCTR-TRC-12002182). 16 Abundance of studies on Chinese herbal medicines for diabetic kidney disease
For this review, we searched the databases, PubMed, Cochrane Library, EMBASE, China National Knowledge Infrastructure, VIP Chinese journal database, Wanfang Database and Chinese Biomedical Literature Database, from inception until 15 August 2015. A total of 932 trials on CHM treatment for diabetic kidney disease were retrieved, indicating that there are numerous herbal formulations and combinations of herbs used to treat DKD. We collated medicinal herbs mentioned in more than 10% of the retrieved trials (Table 1) .
UNDERLYING MECHANISMS OF CHINESE HERBAL MEDICINES IN TREATING DKD
Investigations are revealing the underlying mechanisms of CHMs in treating DKD. Most such studies focus on single herbs and their active chemical compounds. The pathogenesis of DKD is complex, involving chronic inflammation, activation of oxidative stress, uncontrolled apoptosis and lipid nephrotoxicity, ultimately leading to glomerulosclerosis and interstitial fibrosis. Different from chemical agents, the therapeutic effects of CHMs have multiple targets (Fig. 1) .
Astragalus root
Astragalus root (Astragalus membranaceus (Fisch.) Bunge; 黄 芪) is the most common and important Chinese herb used in treating DKD. 17 In vivo and in vitro studies have explored its active compounds and their effects. Astragalus appears to protect the kidney from oxidative stress 18 and rebalance TGF-β/Smad signalling 19 in diabetic rats. Astragaloside IV, a major active component in Astragalus, is considered to have a potent antioxidative 20 and anti-inflammatory 21 effects, as well as endoplasmic-reticulum-stress-induced inhibitory activity, 22 which may suppress mesangial cell proliferation and glomerular contractile dysfunction.
Aibika flower
Huang Kui capsule (黄葵胶囊) is a Chinese patent medicine developed from the aibika flower (Abelmoschus manihot (L.) Medik.; 黄蜀葵花) and is prescribed to treat DKD, nephrotic syndrome and chronic glomerulonephritis. In the diabetic rat model, Huang Kui capsule has been found to attenuate oxidative stress. 23 The primary pharmacologically active constituents of aibika are the total flavone glycosides (TFA). Pre-administration of TFA for 24 weeks showed a significant decrease in proteinuria in streptozotocin-induced DKD rats and alleviation of glomerular cell apoptosis induced by advanced glycation end products. 24 
Cordyceps
Cordyceps (Cordyceps sinensis; 冬虫夏草), or the Chinese caterpillar fungus, is an unusual Chinese herbal medicine. It is a fungus that parasitizes the larvae of ghost moths. The water or alcohol extract of cordyceps has been found to promote glucose metabolism, regulate lipids and suppress oxidation in STZ-induced DKD rats. 25 Cordyceps, together with tripterygium root (Tripterygium wilfordii Hook. F.; 雷公藤), attenuates glomerular damage by preventing the downregulation of podocin and nephrin in DKD rats. 26 Cordyceps can also lower expressions of HIF-1α and VEGF in STZ-induced DKD rats, indicating that cordyceps may protect the kidney against chronic hypoxic injury.
Rhubarb
Rhubarb (Rheum palmatum L.; 大黄) is another common herb used in treating DKD, especially for patients with impaired renal function. The anthraquinones rhein and emodin are the primary active compounds in rhubarb. Rhein has been shown to prevent kidney damage by downregulating the wnt/β-catenin signalling pathway, 28 upregulating SIRT1, 29 decreasing epithelial-mesenchymal transition 30 and ameliorating dyslipidaemia. 31 Emodin has been found to reduce glycation of proteins and decrease mesangial cell proliferation via inhibiting cFLIP, 32 TGF-β1 33 and the p38MAPK pathway. 34 
Tripterygium root
Tripterygium root (Tripterygium wilfordii Hook F.; 雷公藤) is a common herb used to treat proteinuria. 35 Combination of tripterygium with irbesartan showed a reduction in urinary podocyte excretion in DKD patients. 36 Triptolide is the active compound in tripterygium and is reported to have immunosuppressive and anti-inflammatory activities. Pharmacologic studies have demonstrated that the anti-inflammatory effect of triptolide is associated with inhibition of macrophage infiltration 37 and decrease in expression of inflammatory chemokine 38 and cytokines by suppressing activation of nuclear transcription factor NF-kappaB. 39 Triptolide also has an antioxidative effect by inhibiting production of reactive oxygen species and activation of p38-mitogen-activated protein kinase. 40 
Coptis rhizome
In China, coptis rhizome (Coptis chinensis Franch.; 黄连) has long been used to treat diabetes and its complications. Growing evidence suggests that its active compound berberine has renoprotective activities through lowering blood glucose, regulating blood lipids, reducing inflammation and attenuating renal fibrosis. 41, 42 DKD patients administered berberine for 24 months showed improvement in renal haemodynamics and decrease in urinary excretion of the kidney injury biomarker osteopontin and kidney injury molecule-1. 43 Berberine displayed significant suppression of accumulation of extracellular matrix in the kidney through the regulation of the MMP/TIMP system, 44 inhibition of RhoA/ROCK signalling 45 and suppression of the S1P-S1P2 receptor pathway. 46 Berberine may also protect the kidney from injury by modulating the EP4-Gαs-cAMP signalling pathway. 47 Activation of AMP-activated protein kinase is largely involved in the renoprotective effects of berberine. 48 
CONCLUSION
The efficacy of Chinese herbal medicines in treating DKD has been evaluated by numerous basic and clinical studies.
The predominant advantage of CHMs over conventional medicines is in reducing proteinuria effectively. The renoprotective action of CHMs is through multiple pathways, including improving glucose metabolism, reducing dyslipidaemia, modulating haemodynamic disorder, attenuating oxidative stress, suppressing inflammation, inhibiting apoptosis and decreasing the accumulation of extracellular matrix. 
